The Hunger-Blocking Peptide: LEAP2 Reduces Food Intake and Blunts Blood Sugar Spikes in Men With Obesity

In the search for new weapons against obesity, researchers are increasingly looking at the body's own appetite-regulating peptides. A study published in Diabetes in March 2026 highlights one of the most promising: LEAP2 (liver-expressed antimicrobial peptide 2).¹

What Is LEAP2?

LEAP2 was first identified as an antimicrobial peptide, but its role expanded dramatically when scientists discovered it functions as a ghrelin receptor antagonist and inverse agonist.¹ Ghrelin — often called the "hunger hormone" — rises before meals and falls after eating, signaling the brain to seek food. LEAP2 counteracts this system by blocking the ghrelin receptor (GHSR1a), effectively putting the brakes on hunger signaling.

Previous work by the same research group had already shown that LEAP2 administration reduced food intake and plasma glucose levels in preclinical models. This new study took the next step: testing it in humans with obesity.

The Clinical Findings

In men with obesity, LEAP2 administration achieved two notable effects:

1. Reduced ad libitum food intake: Participants consumed less food when allowed to eat freely, suggesting genuine appetite suppression rather than nausea or illness.
2. Attenuated postprandial glucose excursions: Blood sugar spikes after meals were blunted, indicating improved glucose handling independent of the appetite effect.

This dual action — reducing both caloric intake and glycemic variability — positions LEAP2 as a uniquely attractive therapeutic target. Most obesity treatments either focus on appetite suppression or metabolic improvement; LEAP2 appears to address both.

Why This Matters for Peptide Therapeutics

The LEAP2-ghrelin axis represents a relatively new frontier in peptide biology. Unlike GLP-1 receptor agonists, which work through incretin signaling, LEAP2 targets the ghrelin system — a fundamentally different appetite circuit.

This distinction matters because:

• Combination potential: LEAP2-based therapies could potentially complement GLP-1 RAs by targeting a separate hunger pathway, possibly yielding additive or synergistic effects.
• Mechanistic elegance: Rather than introducing an exogenous appetite suppressant, LEAP2 amplifies the body's existing hunger-suppression mechanism.
• Dual metabolic benefit: The glucose-lowering effect adds value beyond weight loss alone.

Looking Ahead

While these results are encouraging, the study was conducted in a relatively small cohort of men with obesity. Larger trials including women, different BMI ranges, and longer follow-up periods will be essential before LEAP2-based therapeutics can move toward clinical development.

Still, for a field that has seen remarkable success with GLP-1 peptide drugs, LEAP2 represents an exciting addition to the peptide therapeutic toolkit — one that works with the body's natural hunger circuits rather than against them.

---

Source: LEAP2 Reduces Ad Libitum Food Intake and Attenuates Postprandial Glucose Excursions in Men With Obesity. Diabetes. 2026 Mar. PMID: 41911360

Footnotes

1. LEAP2 Reduces Ad Libitum Food Intake and Attenuates Postprandial Glucose Excursions in Men With Obesity. Diabetes. 2026 Mar. PMID: 41911360 ↩ ↩²